Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study

References

• Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine. 2002;69:12–8.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552–63.
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93.
   PubMed Web of Science ®Google Scholar
• Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford). 2002;41:430–9.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol. 2008;18:146–52.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, CHANGE Study Investigators. Clinical investiga-tion in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evalua-tion: the CHANGE study. Mod Rheumatol. 2008;18:252–62.
   Google Scholar
• Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruc-tion (RECONFIRM-2J). Mod Rheumatol. 2008;18:447–54.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T, RISING study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheu-matoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19:478–87.
   PubMed Web of Science ®Google Scholar
• Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol. 2004;31:2356–9.
   PubMed Web of Science ®Google Scholar
• Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR, Canete JD. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis. 2004;63:896.
   Google Scholar
• Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13–20.
   Google Scholar
• Karlsson JA, Kristensen LE, Kapetanovic MC, Giilfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhib-itor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:507–13.
   PubMed Web of Science ®Google Scholar
• Matsuno H. Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab. Mod Rheumatol. 2010;20:561–5.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.
   PubMed Web of Science ®Google Scholar
• Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Com-parison of Disease Activity Score (DAS)28-erythrocyte sedi-mentation rate and DA528-C-reactive protein threshold values. Ann Rheum Dis. 2007;66: 407–9.
   Google Scholar
• Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100–8.
   Google Scholar
• Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol. 2010;20:531–8.
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol. 2010;20:343–52.
   PubMed Web of Science ®Google Scholar
• Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. 2007; 66\(Suppl 3):iii56–60
   Google Scholar
• Kiely PD, Brown AK, Edwards CJ, O'Reilly DT, Ostör AJ, Quinn M, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford). 2009;48:765–72.
   Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-con-trolled trial. Ann Rheum Dis. 2008;67:1516–23.
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics. Mod Rheumatol. 2010; 20:40–5.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab mono-therapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.
   PubMed Web of Science ®Google Scholar
• Wakabayashi H, Oka H, Nishioka Y, Hasegawa M, Sudo A, Nishioka K. Do biologics-naïve patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed? A retrospective study. Clin Exp Rheumatol. 2011;29:314–7.
   PubMed Web of Science ®Google Scholar
• Carmona L, Ortiz A, Abad MA. How good is to switch between biologics? A systematic review of the literature. Acta Reumatol Port. 2007;32:113–28.
   Google Scholar